Literature DB >> 25288002

Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling.

Dragana Nikitovic1, Ivo Juranek2, Martin F Wilks3, Maria Tzardi4, Aristidis Tsatsakis5, George N Tzanakakis6.   

Abstract

The mechanisms of anthracycline-dependent cardiotoxicity have been studied widely, with the suggested principal mechanism of anthracycline damage being the generation of reactive oxygen species by iron-anthracycline complexes, leading to lipid peroxidation and membrane damage. An increasing number of researchers studying cardiovascular events associated with anthracycline-based chemotherapy are addressing cardiac extracellular matrix (ECM) remodeling. The heart is an efficient muscular pump, with the cardiomyocytes and intramural coronary vasculature of the heart tethered in an ECM consisting of a network of fibrillar, structural proteins, mostly collagens. Increasing evidence suggests that the ECM plays a complex and diverse role in the processes initiated by anthracycline-class drugs that lead to cardiac damage. This review discusses adverse myocardial remodeling induced by anthracyclines and focuses on their mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25288002     DOI: 10.1378/chest.14-0460

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  Cardiac MRI: a Translational Imaging Tool for Characterizing Anthracycline-Induced Myocardial Remodeling.

Authors:  Kim-Lien Nguyen; Peng Hu; Daniel B Ennis; Jiaxin Shao; Kimberly A Pham; Joseph J Chen
Journal:  Curr Oncol Rep       Date:  2016-08       Impact factor: 5.075

2.  Complementation of the Yeast Model System Reveals that Caenorhabditis elegans OCT-1 Is a Functional Transporter of Anthracyclines.

Authors:  Nicolas Brosseau; Emil Andreev; Dindial Ramotar
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

3.  Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Authors:  Geeta Gulati; Siri Lagethon Heck; Anne Hansen Ree; Pavel Hoffmann; Jeanette Schulz-Menger; Morten W Fagerland; Berit Gravdehaug; Florian von Knobelsdorff-Brenkenhoff; Åse Bratland; Tryggve H Storås; Tor-Arne Hagve; Helge Røsjø; Kjetil Steine; Jürgen Geisler; Torbjørn Omland
Journal:  Eur Heart J       Date:  2016-02-21       Impact factor: 29.983

4.  Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart.

Authors:  Xi-Peng Sun; Li-Li Wan; Quan-Jun Yang; Yan Huo; Yong-Long Han; Cheng Guo
Journal:  Arch Pharm Res       Date:  2017-03-17       Impact factor: 4.946

Review 5.  Mechanistic understanding of nanoparticles' interactions with extracellular matrix: the cell and immune system.

Authors:  Ayse Basak Engin; Dragana Nikitovic; Monica Neagu; Petra Henrich-Noack; Anca Oana Docea; Mikhail I Shtilman; Kirill Golokhvast; Aristidis M Tsatsakis
Journal:  Part Fibre Toxicol       Date:  2017-06-24       Impact factor: 9.400

Review 6.  The microRNA in ventricular remodeling: the miR-30 family.

Authors:  Xiaonan Zhang; Shaoyang Dong; Qiujin Jia; Ao Zhang; Yanyang Li; Yaping Zhu; Shichao Lv; Junping Zhang
Journal:  Biosci Rep       Date:  2019-08-02       Impact factor: 3.840

Review 7.  Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.

Authors:  Marialuisa Framarino-dei-Malatesta; Giuseppina Perrone; Antonella Giancotti; Flavia Ventriglia; Martina Derme; Isabella Iannini; Valentina Tibaldi; Paola Galoppi; Paolo Sammartino; Gianluca Cascialli; Roberto Brunelli
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

Review 8.  Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress.

Authors:  Paweorn Angsutararux; Sudjit Luanpitpong; Surapol Issaragrisil
Journal:  Oxid Med Cell Longev       Date:  2015-09-29       Impact factor: 6.543

Review 9.  Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus?

Authors:  Marialuisa Framarino-Dei-Malatesta; Paolo Sammartino; Angela Napoli
Journal:  BMC Cancer       Date:  2017-11-21       Impact factor: 4.430

10.  Effects of high-intensity interval training on vascular function in breast cancer survivors undergoing anthracycline chemotherapy: design of a pilot study.

Authors:  Kyuwan Lee; Irene Kang; Joanne E Mortimer; Fred Sattler; Wendy J Mack; Lindsey Avery Fitzsimons; George Salem; Christina M Dieli-Conwright
Journal:  BMJ Open       Date:  2018-06-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.